Study wrapper · #225
Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats.
Editor's note
In adult female rats, ipamorelin injected three times daily for 15 days dose-dependently increased the longitudinal growth rate of the tibia (from 42 up to 52 microns/day) and body-weight gain. Notably, this occurred without measurable changes in total IGF-I, IGF-binding proteins, or standard bone turnover markers, an intriguing dissociation since GH's growth effects are usually attributed to IGF-I. The authors are appropriately cautious, stating explicitly that any role in childhood growth retardation would require future clinical studies. Strengths include the direct tetracycline-labelling measure of bone growth and a clear dose-response; limits are the rodent model, short duration, and the unexplained IGF-I finding. For Ipamorelin, this is a mechanistic bone-growth signal in animals, not evidence of a human growth or bone application. Human data are needed before any clinical conclusions.
Plain-language abstract
This study tested whether ipamorelin, a growth-hormone-releasing peptide, affects bone lengthening in rats. Adult female rats received one of several doses (or an inactive control) by injection under the skin three times a day for 15 days. To measure bone growth, the researchers used a fluorescent marker (tetracycline) that binds to newly forming bone, then measured the distance between marked bands in the shin bone. Ipamorelin increased the bone-lengthening rate in a dose-dependent way, from 42 microns per day in controls up to 52 microns per day at the highest dose, and also increased body-weight gain. Unexpectedly, it did not change blood levels of IGF-I or standard markers of bone formation and breakdown. The researchers noted that whether ipamorelin or similar compounds might have a role in children with growth problems would need to be shown in future human studies. This is animal research and does not test effects in people.